Body, Jean-Jacques <br/><br/>
[Inhibition of RANK ligand to treat bone metastases].  [electronic resource] 

 -  Bulletin du cancer  Nov 2013 
 - 1207-13 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1769-6917 
<br/><br/><label>Standard No.: </label>10.1684/bdc.2013.1835  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Bone Density Conservation Agents--adverse effects<br/>Bone Neoplasms--secondary<br/>Breast Neoplasms--complications<br/>Denosumab<br/>Diphosphonates--adverse effects<br/>Female<br/>Humans<br/>Hypocalcemia--chemically induced<br/>Imidazoles--adverse effects<br/>Male<br/>Multiple Myeloma--complications<br/>Prostatic Neoplasms--complications<br/>RANK Ligand--antagonists & inhibitors<br/>Zoledronic Acid